Bone Marrow Failure Research Program
Funding Opportunities for Fiscal Year 2023 (FY23)

The FY23 Defense Appropriations Act provides funding for the Bone Marrow Failure Research Program (BMFRP) to support innovative, high-impact bone marrow failure research.  The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

Applications submitted to the FY23 BMFRP must address one or more of the following Focus Areas:

• Understand the causes and progression of bone marrow failure (BMF) diseases
• Find effective BMF treatments and cures

Idea Development Award
Early Career Investigators:  Independent investigators at the level of Assistant Professor (or equivalent) with less than 10 years from their first faculty appointment (or equivalent)
or
Established Investigators:  Independent investigators at or above the level of Associate Professor (or equivalent) or an Assistant Professor (or equivalent) with 10 years or more from their first faculty appointment by the application submission deadline

•    Preproposal is required; full application submission is by invitation only.
•    Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
•    Research project should include well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach.
•    Translational potential should be considered and described.
•    May include relevant preliminary data. 

Clinical trials are not allowed.

•    Maximum funding of $530,000 in direct costs (plus indirect costs)
•    Period of performance not to exceed 3 years

Investigator-Initiated Research Award (IIRA)
Independent investigators at or above the level of Assistant Professor (or equivalent) by the application submission deadline
•    Preproposal is required; full application submission is by invitation only.
•    Preliminary data are required.
•    Emphasis on Research Approach and Impact.
•    Clinical trials are not allowed.
•    Partnering Principal Investigator (PI) Option:  Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single project.

Funding Level 1  
Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in at least one of the FY23 BMFRP IIRA Focus Areas.
•    Correlative studies to existing clinical trials/studies are encouraged.
•    Translational potential should be considered and described.
Funding Level 2:  Investigational New Drug (IND) application-enabling efforts  

The proposed studies should be empirical in nature, product-driven, and focused on the accumulation of data to support an IND application to the U.S. Food and Drug Administration.  Applications are required to identify lead BMF therapy candidate(s) at time of submission, and transition plans should be considered and adequately described.

Funding Level 1: 
•    Maximum funding of $675,000 in direct costs (plus indirect costs)
•    Period of performance not to exceed 3 years
Funding Level 2: IND-enabling efforts
•    Maximum funding of $850,000 in direct costs (plus indirect costs)
•    Period of performance not to exceed 2 years

See the program announcement for each award

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Point of Contact: 
CDMRP Public Affairs 
301-619-9783 
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil